Circulating tryptophan metabolites and risk of colon cancer: Results from case-control and prospective cohort studies.
Circulating tryptophan metabolites and risk of colon cancer: Results from case-control and prospective cohort studies.
复制标题
DOI：
10.1002/ijc.33725
复制
发表时间：
2021-11-01
影响因子：
6.4
通讯作者：
Keski-Rahkonen P
中科院分区：
文献类型：
--
作者：
Papadimitriou N;Gunter MJ;Murphy N;Gicquiau A;Achaintre D;Brezina S;Gumpenberger T;Baierl A;Ose J;Geijsen AJMR;van Roekel EH;Gsur A;Gigic B;Habermann N;Ulrich CM;Kampman E;Weijenberg MP;Ueland PM;Kaaks R;Katzke V;Krogh V;Bueno-de-Mesquita B;Ardanaz E;Travis RC;Schulze MB;Sánchez MJ;Colorado-Yohar SM;Weiderpass E;Scalbert A;Keski-Rahkonen P
Dysregulation of tryptophan metabolism has been linked to colorectal tumorigenesis, however, epidemiological studies investigating tryptophan metabolites in relation to colorectal cancer risk are limited. We studied associations of plasma tryptophan, serotonin, and kynurenine with colon cancer risk in two studies with cancer patients and controls, and in one prospective cohort: ColoCare Study (110 patients/153 controls), the Colorectal Cancer Study of Austria (CORSA; 46 patients/390 controls), and the European Prospective Investigation into Cancer and Nutrition (EPIC; 456 matched case-control pairs). Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for colon cancer risk. Tryptophan was inversely associated with colon cancer risk in ColoCare [OR per 1-standard deviation (SD) = 0.44; 95% CI, 0.31–0.64] and EPIC (OR per 1-SD = 0.86; 95% CI, 0.74–0.99). Comparing detectable versus non-detectable levels, serotonin was positively associated with colon cancer in CORSA (OR = 6.39; 95% CI, 3.61–11.3) and EPIC (OR = 2.03; 95% CI, 1.20–3.40). Kynurenine was inversely associated with colon cancer in ColoCare (OR per 1-SD = 0.74; 95% CI, 0.55–0.98), positively associated in CORSA (OR per 1-SD = 1.79; 95% CI, 1.27–2.52), while no association was observed in EPIC. The kynurenine-to-tryptophan ratio was positively associated with colon cancer in ColoCare (OR per 1-SD = 1.38; 95% CI, 1.03–1.84) and CORSA (OR per 1-SD = 1.44; 95% CI, 1.06–1.96), but not in EPIC. These results suggest that higher plasma tryptophan may be associated with lower colon cancer risk, while increased serotonin may be associated with a higher risk of colon cancer. The kynurenine-to-tryptophan ratio may also reflect altered tryptophan catabolism during colon cancer development.
登录
查看更多内容
影响因子：
--
作者：
Nishiumi S;Kobayashi T;Kawana S;Unno Y;Sakai T;Okamoto K;Yamada Y;Sudo K;Yamaji T;Saito Y;Kanemitsu Y;Okita NT;Saito H;Tsugane S;Azuma T;Ojima N;Yoshida M
通讯作者：
Yoshida M
血清色氨酸降低与结直肠癌的免疫激活和生活质量受损相关。
影响因子：
8.8
作者：
Huang, A;Fuchs, D;Widner, B;Glover, C;Henderson, D C;Allen-Mersh, T G
通讯作者：
Allen-Mersh, T G
影响因子：
8.9
作者：
Lihn, AS;Pedersen, SB;Richelsen, B
通讯作者：
Richelsen, B
影响因子：
6.4
作者：
Geijsen, Anne J. M. R.;van Roekel, Eline H.;Kok, Dieuwertje E.
通讯作者：
Kok, Dieuwertje E.
影响因子：
5
作者：
Lindstrom, Mikael;Tohmola, Niina;Itkonen, Outi
通讯作者：
Itkonen, Outi